Expression of vascular endothelial growth factor and KDR in papillary thyroid carcinoma with extracapsular invasion [Factor de crecimiento de endotelio vascular y su relación clínica en carcinomas papilares de tiroides con invasión extracapsular]

Abstract

Paratuberculosis (PTB) is a chronic disease caused by M. avium subsp. paratuberculosis (MAP) that affects several animal species, and some studies have suggested that there may be a relationship between Crohn's disease and PTB. Significant aspects of PTB pathogenesis are not yet completely understood, such as the role of macrophages. Natural resistance-associated macrophage protein 1 (NRAMP1) and the inducible nitric oxide synthase (iNOS) molecules have shown nonspecific effects against several intracellular pathogens residing within macrophages. However, these molecules have been scarcely studied during natural infection with MAP. In this work, changes in NRAMP1 and iNOS expression were surveyed by immunohistochemistry in tissue samples from MAP-infected cattle and healthy controls. Our findings show strong specific immunolabeling against both NRAMP1 and iNOS molecules, throughout granulomatous PTB-compatible lesions in ileum and ileocaecal lymph nodes from paratuberculous cattle compared with uninfected controls, suggesting a relationship between the expression of these molecules and the pathogenesis of PTB disease. " 2009 Elsevier Ltd.",,,,,,"10.1016/j.cimid.2009.03.001",,,"http://hdl.handle.net/20.500.12104/41412","http://www.scopus.com/inward/record.url?eid=2-s2.0-77955927714&partnerID=40&md5=654cd0e27889cdbb2d44f3913c68d6bd",,,,,,"5",,"Comparative Immunology, Microbiology and Infectious Diseases",,"389

400",,"33",,"Scopus

WOS",,,,,,"Cattle; Johne's disease; MAP; NRAMP1; Paratuberculosis; Slc11a1 and iNOS",,,,,,"Expression of NRAMP1 and iNOS in Mycobacterium avium subsp. paratuberculosis naturally infected cattle",,"Article" "43193","123456789/35008",,"Torres-Reyes, L.A., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de GuadalajaraGuadalajara, Jalisco, Mexico; Alvarado-Ruiz, L., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de GuadalajaraGuadalajara, Jalisco, Mexico; Piña-Sánchez, P., Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Centro Médico Nacional Siglo XXI-IMSS, Mexico; Martínez-Silva, M.G., Servicio de Patología, Centro Médico Nacional de Occidente-IMSSGuadalajara, Jalisco, Mexico; Ramos-Solano, M., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de GuadalajaraGuadalajara, Jalisco, Mexico; Olimón-Andalón, V., Escuela de Biología, Universidad Autónoma de Sinaloa. CuliacánSinaloa, Mexico; Ortiz-Lazareno, P.C., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico; Hernández-Flores, G., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico; Bravo-Cuellar, A., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico; Aguilar-Lemarroy, A., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico; Jave-Suarez, L.F., División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS)Guadalajara, Jalisco, Mexico",,"Torres-Reyes, L.A.

Alvarado-Ruiz, L.

Pina-Sanchez, P.

Martinez-Silva, M.G.

Ramos-Solano, M.

Olimon-Andalon, V.

Ortiz-Lazareno, P.C.

Hernandez-Flores, G.

Bravo-Cuellar, A.

Aguilar-Lemarroy, A.

Jave-Suarez, L.F.",,"2014",,"The transcription factor grainyhead-like 2 (GRHL2) is evolutionarily conserved in many different species, and is involved in morphogenesis, epithelial differentiation, and the control of the epithelial-mesenchymal transition. It has also recently been implicated in carcinogenesis, but its role in this remains controversial. Expression of GRHL2 has not previously been reported in cervical cancer, so the present study aimed to characterize GRHL2 expression in cervical cancer-derived cell lines (CCCLs) and cervical tissues with different grades of lesions. Microarray analysis found that the expression of 58 genes was down-regulated in CCCLs compared to HaCaT cells (non-tumorigenic human epithelial cell line). The expression of eight of these genes was validated by quantitative real-time PCR (qPCR), and GRHL2 was found to be the most down-regulated. Western blot assays corroborated that GRHL2 protein levels were strongly down-regulated in CCCLs. Cervical cells from women without cervical lesions were shown to express GRHL2, while immunohistochemistry found that positivity to GRHL2 decreased in cervical cancer tissues. In conclusion, a loss or strong reduction in GRHL2 expression appears to be a characteristic of cervical cancer, suggesting that GRHL2 down-regulation is a necessary step during cervical carcinogenesis. However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression.",,,,,,,,,"http://hdl.handle.net/20.500.12104/41414","http://www.scopus.com/inward/record.url?eid=2-s2.0-84919493948&partnerID=40&md5=897fc80c9537b8653fa8c8e500ce464f

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25550776",,,,,,"11",,"International Journal of Clinical and Experimental Pathology",,"7409

7418",,"7",,"Scopus

MEDLINE

WOS",,,,,,"Carcinogenesis; Cervical cancer; Epithelial-mesenchymal transition; Grainyhead-like 2; GRHL2",,,,,,"Expression of transcription factor grainyhead-like 2 is diminished in cervical cancer",,"Article" "43188","123456789/35008",,"Vázquez-del Mercado, M., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Delgado-Rizo, V., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Muñoz-Valle, J.F., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Orozco-Alcalá, J., Hospital Civil de Belén, Mexico; Volk, H.-D., Institute for Medical Immunology, University of Berlin, Germany; Armendáriz-Borunda, J., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico",,"Vazquez-del Mercado, M.

Delgado-Rizo, V.

Munoz-Valle, J.F.

Orozco-Alcala, J.

Volk, H.-D.

Armendariz-Borunda, J.",,"1999",,"Objective: To determine IL-1?, TNF?, IL-6, IL-4, IL-10, MMP-1, MMP-3 and MMP-13 expression by freshly isolated peripheral blood (PBMC) and synovial fluid mononuclear cells (SFMC) in early, never-treated (ENT-RA) and non-acute, treated rheumatoid arthritis (NAT-RA) patients. To elucidate whether excessive or inadequate interleukin (IL) and metalloprotease (MMP) expression is influenced by the disease duration. Methods: Fourteen RA patients, 7 with early RA (< 1 year of evolution) never treated with corticosteroids or disease-modifying antirheumatic drugs, and 7 patients with non-acute RA (> 2 years of evolution) treated with disease-modifying antirheumatic drugs, were studied by ELISA and quantitative and semiquantitative RT-PCR. A group of 14 healthy subjects matched for sex and age was included. Results: No statistically significant difference in the protein or transcript levels for the cytokines of interest was found between the ENT-RA and NAT-RA groups. The cytokine mRNA expression by freshly isolated PBMC and SFMC in both groups was as follows: IL-1? > TNF? > IL-10 > IL-6, with no mRNA IL-4 expression. In contrast, cytokine serum levels in ENT-RA and NAT-RA patients were detected in inverse order as follows: IL-6 > IL-10, while IL-1?, TNF? and IL-4 were undetectable. MMP-3 mRNA expression by the PBMC of NAT-RA patients was statistically different to that in ENT-RA patients. Similar levels of mRNA expression of MMP-1, MMP-3 and MMP-13 by the PBMC and SFMC in both RA groups were observed. Conclusions A close equilibrium between MMP and pro/anti-inflammatory cytokine production is observed in ENT-RA and NAT-RA patients. This balance is apparently not influenced by the length of the disease. Highly sensitive methods such as quantitative RT-PCR and ELISA, and even studying freshly isolated MC, showed sustained cytokine secretion at the local level (synovial fluid/SFMC) and scarce translation at the peripheral level (serum/PBMC). Expression of MMP mRNA needs to be further evaluated in order to know whether their peripheral expression reflects their local activity in RA patients.",,,,,,,,,"http://hdl.handle.net/20.500.12104/41409","http://www.scopus.com/inward/record.url?eid=2-s2.0-0032858456&partnerID=40&md5=1ec8f38042f2881f339ce525dd68e542

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10544841",,,,,,"5",,"Clinical and Experimental Rheumatology",,"575

583",,"17",,"Scopus

MEDLINE

WOS",,,,"Index Medicus;Acute Disease;Adult;Antirheumatic Agents/ad [Administration & Dosage];Antisense Elements (Genetics);Arthritis, Rheumatoid/dt [Drug Therapy];Arthritis, Rheumatoid/ge [Genetics];Arthritis, Rheumatoid/im [Immunology];Chronic Disease;Collagenases/ge [Genetics];Female;Gene Expression Regulation, Enzymologic/im [Immunology];Humans;Interleukin-1/ge [Genetics];Interleukin-10/ge [Genetics];Interleukin-4/ge [Genetics];Interleukin-6/ge [Genetics];Interleukins/ge [Genetics];Leukocytes, Mononuclear/en [Enzymology];Leukocytes, Mononuclear/im [Immunology];Male;Matrix Metalloproteinase 1/ge [Genetics];Matrix Metalloproteinase 13;Matrix Metalloproteinase 3/ge [Genetics];Matrix Metalloproteinases/ge [Genetics];Middle Aged;RNA, Messenger/an [Analysis];Reverse Transcriptase Polymerase Chain Reaction;Synovial Fluid/ch [Chemistry];Synovial Fluid/en [Enzymology];Synovial Fluid/im [Immunology];Tumor Necrosis Factor-alpha/ge [Genetics]",,"Cytokines; Mononuclear cells; Quantitative RT-PCR; Rheumatoid arthritis; Synovial fluid",,,,,,"Expression of interleukin-1?, tumor necrosis factor ?, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients",,"Article" "43196","123456789/35008",,"González, R.G., Centro Interdisciplinario de Ciencias de la Salud, Departamento de Ciencias Morfofisiológicas, Instituto Politécnico Nacional (CICS-IPN), México DF, Mexico; Molina, R.B., Instituto de Investigaciones Odontológicas, Universidad de Guadalajara (U de G) Guadalajara, México, Mexico; Frechero, N.M., Departamento de Atención a la Salud, Universidad Autónoma Metropolitana, México, Mexico; Rosas, G.A., Instituto Dermatológico de Jalisco Dr. José Barba Rubio, Mexico; Roaf, P.M., Instituto de Investigaciones Odontológicas, Universidad de Guadalajara (U de G) Guadalajara, México, Mexico; Martínez, C.P.M., Centro Interdisciplinario de Ciencias de la Salud, Departamento de Ciencias Morfofisiológicas, Instituto Politécnico Nacional (CICS-IPN), México DF, Mexico; Prado, I.C., Centro de Investigaciones, Universidad de Cuautitlan Izcalli (CIUCI), Mexico; Malagon, H.D., Departamento de Patología Quirúrgica, Instituto Nacional de Cancerología, México. (INCan), Mexico",,"Gonzalez, R.G.

Molina, R.B.

Frechero, N.M.

Rosas, G.A.

Roaf, P.M.

Martinez, C.P.M.

Prado, I.C.

Malagon, H.D.",,"2009",,"Angiogenesis is important in the growth and progression of tumours. Vascular endothelial growth factor (VEGF) is the most important factor in vascular neoformation and an increase in its expression is associated with tumour progression and a worse prognosis. The purpose of this study is to evaluate the expression of VEGF-A and its receptor KDR/VEGF-2 in papillary thyroid carcinomas (PTC), larger or smaller than 10 mm, and with or without extracapsular extension (PTC-E and PTC-NE). Methods: VEGF-A and KDR were studied with tissue microarray (TMA) in a total of 62 cases of PTC-E and PTC-NE larger and smaller than 10mm. Results: the positivity of VEGF-A and KDR was predominantly similar in PTC-E and PTC-NE with no statistical significance between tumour size and PTC-E and PTC-NE. However, the intensity of expression was higher for PTC-E >10mm, while KDR was more frequently expressed in PTC-NE ?10mm. The intensity was similar for both groups and sizes. Conclusion: the results obtained correlate with previously published results, however, there are no reports in the literature related to the correlation of extracapsular extension and VEGF-A and KDR. Whereas the expression of KDR was similar in both groups, VEGFA was higher in PTC-E >10mm, which would indicate that an over expression of VEGF-A may be related to extracapsular invasion. " 2009 Sociedad Española de Anatomóa Patológica y Sociedad Española de Citología.